- Exchange: EN Paris
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Transgene SA
+ Add to WatchlistTNG:FP
9.4800 EUR 0.1500 1.61%
Share
As of 11:35:00 ET on 05/22/2013.
More on TNG
News for Transgene SA (TNG)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Modified Smallpox Vaccine Stymies Liver Cancer in Study
- Transgene Won’t Sign TG4040 Partnership Soon, CEO Says
- PsiOxus Starts Human Tests of Cancer Vaccine
- Comdirect, JCDecaux, L’Oreal, Repsol YPF May Move: European Equity Preview
- Transgene’s Boissel Says a Dozen Companies Interested in TG4040
- Transgene, Jennerex Cancer Therapy Improves Survival in Study
- Transgene Experimental Drug Kept Lung Cancer at Bay in Study
- GDF Suez, Rhodia, Sanofi, Transgene: French Equity Preview
- BP, Hays, Sonae SGPS, Transgene: European Equity Preview
- French Stocks: Alcatel, Bollore, Bourbon, Renault, Zodiac Move
- Transgene Says Experimental Cancer Drug Has ‘Enormous Potential’
- European Stocks Decline as Libyan Unrest Continues; Shares of OMV Retreat
- Transgene Falls After Roche Ends Licensing Agreement
- Accor, Natixis, Rhodia, Tharreau, Vivendi: French Equity Preview
- Transgene in Talks to License Experimental Antibody Showing Cancer Promise
- Transgene Announces Completion of Enrollment in TRAVERSE, a Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Published May 21, 2013
- Transgene Announces its Invesment in ElsaLys Biotech, a New Antibody Company Created by Former Executives Published May 21, 2013
- The start-up ElsaLys Biotech, a new player in the therapeutic monoclonal antibody arena, announces the first round of financing Published May 17, 2013
- Transgene Announces that Clinical Data with Pexa-Vec will be Presented at the 2013 American Society of Clinical Oncology Annual Published May 15, 2013
- Transgene: Promising Final Data from the Phase 2 HCVac Trial of TG4040 Presented at EASL 2013 Published Apr 29, 2013
- Transgene Presents Promising Pre-Clinical Data on TG1050 to Treat Chronic HBV at EASL 2013 Published Apr 29, 2013
- TRANSGENE FIRST-QUARTER REVENUE EU3.64 MLN VS EU3.63 MLN Published Apr 22, 2013
- Transgene : First Quarter 2013 Financial Report Published Apr 22, 2013
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail Updated 4 hours ago
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says Updated 4 hours ago
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page